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ABSTRACT 
Selective targeting of the tumor cell mitochondrion is a viable approach for the 
development of anti-cancer agents because the organelle is functionally different from that in 
normal cells. We recently developed a novel aryl-urea fatty acid (1; 16({[4-chloro-3-
(trifluoromethyl)phenyl]carbamoyl}amino)hexadecanoic acid) that disrupted the 
mitochondrion and activated apoptosis in MDA-MB-231 breast cancer cells. However, 
currently there is little information on the structural requirements for activity of 1 analogues. 
The present study evaluated the role of the carboxylic acid group on the anti-cancer activity of 
1. Bioisosteric replacement of the carboxylate in 1 maintained activity. Thus, like 1, the 
sulfonic acid analogue 1-SA and the oxo-thiadiazole analogue 1-OT also targeted the 
mitochondrion and activated cell killing capacity. The hydroxamic acid analogue 1-HA also 
killed MDA-MB-231 cells, but its onset of action was slower than 1-SA and 1-OT. In contrast, 
replacement of the carboxylate with non-bioisosteric amido- and methylamido-groups 
produced analogues that minimally altered mitochondrial function and showed little capacity 
to decrease tumor cell viability. These findings suggest that the carboxylate moiety in the novel 
mitochondrially-targeted agent 1 is an important determinant of the kinetics and efficacy of 
anti-cancer cell activities of 1 analogues. Further development of carboxylate-modified 
analogues of aryl-urea fatty acids as potential anti-cancer agents could now be warranted. 
 




Agents that kill cancer cells by novel mechanisms are required to develop new anti-cancer 
therapeutics and to induce further remissions in cancer patients who are resistant to established 
agents. The tumor cell mitochondrion is functionally distinct from mitochondria in normal cells 
and is a promising target for anti-cancer drug development because it regulates both apoptotic 
cell death and the synthesis of macromolecules that are required for the rapid proliferation of 
tumor cells.[1] 
Polyunsaturated fatty acids (PUFAs) are metabolised in cells to diverse lipid mediators, 
including prostaglandins, leukotrienes and epoxides, and secondary biotransformation 
products, that are important modulators of homeostasis.[2] While cytochrome P450 (CYP) 
enzymes have been most widely studied for their roles in the biotransformation of drugs, 
natural products and other xenobiotics,[3-6] several are also active in PUFA oxidation. CYP-
derived epoxyeicosatrienoic acids (or EETs) are formed from the ω-6 PUFA arachidonic acid 
and promote tumorigenesis,[7] while a number of their ω-3 PUFA-derived counterparts are anti-
tumorigenic.[8,9] Thus, we found that ω-3-17,18-epoxyeicosapentaenoic acid and its fully-
saturated analogue impaired cell viability by decreasing proliferation and activating 
apoptosis.[8,10] Others have reported that docosahexaenoic acid epoxides prevent tumor 
progression.[9] However, unless coadministered with epoxide hydrolase inhibitors, the 
instability of ω-3 epoxides in vivo, due to rapid deactivation by soluble epoxide hydrolase, 
prevents their use as anti-cancer agents.[9,11] Replacement of the epoxide moiety with urea has 
been used to generate mimetics of ω-3[12] and ω-6[13,14] epoxides. We recently reported the 
development of a ω-terminal aryl-urea analogue of ω-3-17,18-epoxyeicosatetraenoic acid 
(termed 1; see Scheme 1 for structure) that targeted the mitochondrion in MDA-MB-231 breast 
cancer cells to activate apoptotic cell death.[15]  
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1 is a new lead compound with promising anti-cancer activity, but we are yet to determine 
which pharmacophoric groups in its structure are essential for activity. The present study was 
designed to investigate the importance of the carboxylic acid functionality on anti-cancer 
activity in human MDA-MB-231 cells by preparing 1 analogues in which the carboxylate 
group was replaced with non-bioisosteric amide functionalities (1-A and 1-MA; Scheme 1). 
We also prepared 1 analogues containing carboxylate bioisosteres from different structural 
classes. Thus, the hydroxamic acid (1-HA; Scheme 1), the planar heterocyclic oxo-thiadiazole 
(1-OT) and the non-planar sulfur-derived sulfonate (1-SA; Scheme 2) isosteres were evaluated. 
The principal finding to emerge was that this region was an important determinant of the 
potency and kinetics of the activity of 1 analogues in tumor cells; the analogues exhibited 
varying ability to target the mitochondrion and elicit cell death. 
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Scheme 1: Synthesis of the amide analogues 1-A and 1-MA, and the hydroxamic acid analogue 
1-HA. Reagents and conditions: (i) EDCI, HOBT and NMM, and then either ammonium 




Synthesis of aryl-urea carboxylate analogues. The amide derivatives 1-A and 1-MA 
were prepared by reactions of 1 with ammonium chloride or methyl ammonium chloride, 
respectively, using N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) 
as a coupling reagent to form the amide bonds (Scheme 1). At completion of both reactions 
water was added to precipitate the products, which were isolated by filtration. The hydroxamic 
acid 1-HA was also synthesised from 1 using EDCI coupling (Scheme 1).[16] In the first step 1 
was reacted with O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine to yield 2, a tetrahydropyranyl 
ether-protected intermediate of 1-HA.[17] Deprotection of 2 was achieved using hydrochloric 
acid in methanol, yielding 1-HA as a precipitate that was isolated by filtration and purified by 
trituration with methanol/water (50:50), followed by acetone.  
The key intermediate in the synthesis of 1-SA and 1-OT was the bromourea 7, which 
was prepared using an adaptation of the procedure of Miwa et al. (Scheme 2).[18] 15-
Bromopentadecan-1-ol (3) was refluxed with potassium phthalimide to produce the 
intermediate 4 that was hydrolysed by refluxing with hydrazine to generate the primary amine 
5. The alcohol group in 5 was converted to a bromide using concentrated hydrobromic acid, 
yielding 6 as the hydrobromide salt that was purified by recrystallisation in acetone. The 
bromourea 7 was obtained by reacting 6 with 4-chloro, 3-(trifluoromethyl)phenylisocyanate in 
the presence of triethylamine, which served as a base to generate the free amine from the 
hydrobromide salt of 6.  
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Scheme 2: Synthesis of oxo-thiadiazole (1-OT) and sulfonic acid (1-SA) isosteres. Reagents 
and conditions: (i) potassium phthalimide, anhydrous DMF, N2, reflux, 18 h; (ii) hydrazine, 
THF, reflux, 18 h; (iii) HBr, reflux, 18 h; (iv) 4-chloro-3-(trifluoromethyl)phenyl isocyanate, 
triethylamine, anhydrous THF, N2, rt, 4 h; (v) sodium sulfite, ethanol/water (3:2), reflux, 3 d; 
(vi) NaCN, 40°C, DMSO, 24 h; (vii) HONH2, methanol, reflux, 18 h; (viii) a. 1,1′-
thiocarbonyldiimidazole, anhydrous THF, rt, 2 h; b. diazabicycloundec-7-ene, ACN, 90°C to 
rt, 18 h. 
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The sulfonic acid derivative 1-SA was prepared by refluxing bromourea 7 with sodium 
sulfite in aqueous ethanol for three days. The oxo-thiadiazole 1-OT was obtained by reacting 
7 with sodium cyanide in DMSO and the resultant nitrile 8 was then treated with aqueous 
hydroxylamine solution to generate the amidoxime 9. Subsequently, 9 was reacted with 1,1′-
thiocarbonyldiimidazole in acetonitrile to form the oxo-thiadiazole ring and yield 1-OT.[19]  
Impaired ATP production by analogues of 1 in breast cancer cells. Treatment of 
triple-negative MDA-MB-231 breast cancer cells with 1-OT and 1-SA (10 µM, 24 h) 
decreased ATP production to 33±4% (P<0.001) and 69±8% (P<0.05) of control, respectively. 
In comparison, 1 decreased ATP production to 72±14% of control (P<0.05; Figure 1A). Longer 
term treatment for 48 h produced more pronounced effects. Thus, 1-OT strongly decreased 
ATP production to 5±1% of control (P<0.001), while the activities of 1 and 1-SA were also 
greater (Figure 1A). Interestingly, the hydroxamic acid derivative 1-HA was highly active after 
48 h of treatment despite its low activity at 24 h, while 1-A and 1-MA exerted minimal effects 
on ATP production even after 48 h of treatment. 
 
Figure 1 (below): (A) Effect of 1 analogues (10 µM) on ATP formation by MDA-MB-231 
cells after 24 and 48 h of treatment; (B) Flow cytometric analysis of MDA-MB-231 cells after 
treatment with 1 analogues (10 µM) for 24 and 48 h. Areas in histograms corresponding to sub-
G1, G0/G1, S and G2/M phases are shown in control (CTL) cells. Histograms were obtained 
after 24 h unless indicated otherwise. All data are mean±SEM from three separate experiments. 
Different from DMSO-treated control: ***P<0.001, **P<0.01, *P<0.05. 
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To corroborate the effects on ATP production, the impact of the 1 analogues on cell 
cycle kinetics was investigated by flow cytometry. After 24 h of treatment 1 and 1-OT (10 
µM) strongly increased the proportion of cells in sub-G1 phase to ~10-fold of control and 
altered the cell populations in S and/or G2/M phase (Figure 1B); these changes were more 
pronounced after 48 h. 1-SA produced a trend toward increased sub-G1 content to 1.8 and ~4-
fold of control at 24 and 48 h, respectively, and increased the accumulation of cells in G2/M 
phase. Treatment of cells with 1-HA altered the cell cycle distribution at both 24 and 48 h, 
whereas treatment for 48 h was required to increase sub-G1 phase (Figure 1B). Together these 
findings indicate that the carboxylate analogues of 1 - namely 1-OT, 1-HA and 1-SA - impaired 
the viability of MDA-MB-231 cells by decreasing energy production and cell cycle 
progression. In contrast, 1-A and 1-MA (10 µM) did not markedly alter the cell cycle 
distribution from control after 24 and 48 h treatment (Figure 2B). 
Activation of apoptosis by aryl-ureas. The increase in sub-G1 phase elicited by 
several analogues implicated apoptotic cell death in the mechanism of cell impairment. 
Accordingly, we further assessed the capacity of the most effective analogues to activate 
apoptosis in MDA-MB-231 cells by measuring the activity of the executioner caspases-3/7 
(Figure 2A). After 24 h, 1 (10 µM) increased caspase-3/7 activity to 3.7-fold of control 
(P<0.01). In comparison, 1-OT (10 µM) increased caspase activity to ~5.9-fold of control at 
24 h (P<0.001), while 1-SA (10 µM) produced a lesser increase to 2.7-fold of control (P<0.05). 
At 48 h the activation by 1-SA seen at 24 h was sustained, while 1-HA also exhibited activity 
(~3.5-fold of control). In contrast, the marked increase produced by 1-OT by 24 h of treatment 
was decreased in magnitude to ~2.3-fold of control by 48 h. The capacity of 1 and its analogues 
to increase caspase-3 activity was also assessed in non-cancerous MCF10A cells, which are 
used commonly as a control breast cell line. None of the analogues significantly increased 
caspase-3 activity when tested at a concentration of 10 µM. 
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To further substantiate the capacity of the active analogues to elicit cell death, MDA-
MB-231 cells were subjected to annexin V-FITC/7-aminoactinomycin D (annexin V/7AAD) 
staining (Figure 2B). Strong increases in dual-stained and annexin V-stained cells after 48 h of 
treatment are consistent with increased late and early apoptosis produced by 1, 1-OT and 1-
SA to ~4-5-fold of corresponding control. In contrast, 1-HA strongly increased 7AAD-staining 
and, to a lesser extent, dual staining to ~2-fold of control, while annexin V staining was 
essentially unchanged from control. These findings suggest that necrosis may be an important 
death process in the case of that analogue. However, after 24 h of treatment 1-HA did not 
activate cell death. In view of these time-dependent effects of 1-HA on cell viability, we also 
tested the other active agents at 24 h. Similar changes to those at 48 h were also noted at 24 h 
with 1 and 1-SA, but 1-OT effected a pronounced increase in dual-stained cells to ~11-fold of 
control that decreased by 48 h, consistent with findings from caspase-3/7 assays (Figure 2A) 
and suggesting that extensive cell deletion occurred rapidly with that analogue.  
 
 
Figure 2 (below): (A) Effect of 1 analogues (10 µM) on caspase-3/7 activity in MDA-
MB-231 cells after 24 and 48 h of treatment; (B) annexin V-FITC/7AAD staining in MDA-
MB-231 cells after treatment with 1 analogues (10 µM) for 24 or 48 h. Areas corresponding to 
7AAD-stained cells (upper left quadrant), annexin V-stained cells (lower right quadrant), dual 
7AAD and annexin V-stained cells (upper right quadrant) and unstained live cells (lower left 
quadrant) are shown in control (CTL) cells. Images showing cell distributions were obtained 
after 24 h of treatment; (C) JC-1 ratios in MDA-MB-231 cells treated with various 
concentrations of 1 analogues. All data are mean±SEM from three separate experiments. 






Aryl urea analogues target the mitochondrial membrane in MDA-MB-231 cells. 1 
has been found previously to target the mitochondrion in MDA-MB-231 cells.[15]  We assessed 
whether the present carboxylate-modified aryl-urea fatty acids also effected mitochondrial 
disruption using the membrane-permeable redox-active cationic dye JC-1. JC-1 forms 
aggregates that fluoresce red in the electronegative environment of the intact inner 
mitochondrial membrane. In damaged mitochondria that have lost their membrane potential, 
JC-1 remains in the cytoplasm in its monomeric form, which fluoresces green. As expected, 1 
treatment (1 h) rapidly decreased the red:green fluorescence ratio in JC-1 stained cells in a 
concentration-dependent fashion (IC50 ~4.7 µM; Figure 2C). 1-OT was similarly effective 
(IC50 ~4.6 µM) and 1-SA also targeted the mitochondrion, but was less effective than 1 or 1-
OT (IC50 ~19 µM). Neither 1-HA or the inactive amides 1-A and 1-MA altered the JC-1 
red:green ratio over the concentration range 1-20 µM at 1 h (Figure 2C). In further studies, 
longer-term treatment with 1-HA, 1-A and 1-MA for up to 24 h also minimally altered the JC-
1 ratio (decreases to 81-89% of control at a test concentration of 20 µM; data not shown). 
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DISCUSSION 
The development of well-tolerated anti-cancer agents with novel mechanisms of action 
could provide valuable options in the treatment of cancer patients. The long-chain fatty acid 
derivative 1 was recently identified as the first in a new class of potential anti-cancer agents 
with activity against MDA-MB-231 breast cancer cells.[19] The present study assessed the 
importance of the carboxylic acid group in the activity of 1. Replacement of this moiety with 
non-bioisosteric amide groups found in 1-A and 1-MA led to inactive compounds, indicating 
that the carboxylate group is required for activity. Consistent with the carboxylate being part 
of the pharmacophore, the carboxylate bioisosteres 1-OT, 1-HA and 1-SA were active and 
strongly decreased the viability of MDA-MB-231 breast cancer cells.  
The most active analogues (1-OT, 1-HA and 1-SA) decreased cellular energy 
production as ATP. Arrest of cell cycle progression by the active analogues is consistent with 
decreased energy metabolism, and the accumulation of cells in S and/or G2M phases is 
consistent with prevention of DNA replication and cell proliferation. After 48 h of treatment 1, 
1-OT, 1-HA and 1-SA also activated cell death, as reflected by the increases in the proportion 
of cells in sub-G1 phase, caspase-3/7 activity and annexin V/7AAD staining. The increase in 
annexin V-FITC/7AAD staining by active carboxylate modified analogues of 1 suggests that 
cell killing is mediated by the dual mechanisms of apoptosis and necrosis. Apoptosis appears 
to be the major death mechanism that is initially activated by 1, 1-OT and 1-SA in treated cells. 
Subsequent disruption of the plasma membrane following prolonged treatment with active 
analogues reflects the activation of necrosis and enables DNA staining by 7AAD. Similar to 
aryl urea 1, the analogues 1-OT and 1-SA induce cell death by collapsing the mitochondrial 
membrane potential, as reflected by a shift in the JC-1 red:green fluorescence ratio of cells 
following treatments. 1-HA did not alter the JC-1 ratio over the 24 h timeframe of these 
experiments, which is consistent with a delayed onset of action that was also noted in other 
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assays. Taken together, the carboxylic acid functional group can be replaced with several 
moieties to retain the anti-proliferative and pro-apoptotic activity of 1 in MDA-MB-231 breast 
cancer cells. 
The activity of 1-OT suggests that planar heterocyclic moieties may also be effective 
carboxylate isosteres. We attempted to prepare a tetrazole-containing bioisostere of 1 but were 
unable to synthesise this compound from bromourea 7 using established approaches. 
Interestingly, the hydroxamic acid analogue 1-HA displayed different kinetics to 1, 1-SA and 
1-OT, and required 48 h to produce extensive loss of cell viability. Unlike the other active 
agents evaluated in this study, 1-HA did not disrupt the mitochondrial membrane potential and 
appeared to activate necrotic death in a delayed fashion, rather than by the rapid activation of 
apoptosis produced by other analogues. Our ongoing studies to identify the cellular target(s) of 
1 analogues may eventually assist with a more complete interpretation of the present findings.   
In cancer cells the mitochondrion could contain novel drug targets because it is 
structurally and functionally different from the organelle in normal cells.[1] Whereas oxidative 
phosphorylation is the primary pathway by which ATP is generated in normal cells, aerobic 
glycolysis is more important in highly aggressive tumors cells (the Warburg effect).[20] Instead, 
the cancer cell mitochondrion is involved in the increased production of the macromolecules 
that are necessary for tumor cell replication.[1] The mitochondrion is also a critical regulator of 
apoptotic cell death and in cancer cells these pathways are frequently less responsive to 
cytotoxic agents. Thus, the development of novel agents that selectively damage the 
mitochondrion in tumor cells could lead to the development of new therapeutic strategies.[2,23] 
Recently 1 emerged as the first in a new class of agents with activity against cancer cells 
produced by rapid targeting of the tumor cell mitochondrion. It now emerges that the analogues 
1-OT and 1-SA, but not the amides 1-A and 1-MA, also disrupt the mitochondrion to promote 
extensive tumor cell destruction.   
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CONCLUSION 
In summary, we have prepared analogues of the novel anticancer agent 1 in which the 
carboxylate group was modified with bioisosteric and non-bioisosteric groups. Substitutions 
with bioisosteric groups produced active analogues. Like 1 the oxo-thiadiazole and the sulfonic 
acid derivatives 1-OT and 1-SA effectively disrupted the mitochondrial potential and promoted 
cell death, while the hydroxamic derivative 1-HA had a delayed onset of action relative to 1, 
which appeared to be unrelated to mitochondrial targeting. The inactivity of the non-
bioisosteric amide derivatives 1-A and 1-MA indicates that the carboxylate group of 1 is part 





General: All reagents and anhydrous solvents were purchased from Sigma Aldrich (Castle 
Hill, NSW, Australia). Dry Column Vacuum Chromatography was used to purify reaction 
products on silica gel with gradient elutions. TLC was performed on silica gel 60 F254 plates. 
Melting points were measured on a Stuart SMP10 melting point apparatus. 1H and 13C NMR 
spectra were recorded on an Agilent 500 MHz NMR. Spectra were referenced internally to 
residual solvent (CDCl3; 
1H  7.26, 13C  77.10. d6-DMSO; 
1H  2.49, 13C  39.52). High 
resolution mass spectrometry (HRMS) was performed on an Agilent Technologies 6510 Q-
TOF LCMS.  
 
General procedure for synthesis of amides 1-A and 1-MA: To a solution of 1 (0.150 g, 
0.304 mmol) in anhydrous DMF (10 mL) under nitrogen were added 1-hydroxybenzotriazole 
hydrate (0.060 g, 0.365 mmol), NMM (0.100 mL, 0.912 mmol) and EDCI (0.082 g, 0.426 
mmol). The solution was stirred at room temperature for 30 min, then NH4Cl or methylamine 
HCl (0.942 mmol) was added and stirring was continued for 18 h. Distilled water (10 mL) was 
added, and the solid collected by filtration, washed with water and diethyl ether, affording the 
amide as a white solid. 
16-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]hexadecanamide (1-A): White 
solid, yield 30%. Mp = 129-132C. 1H NMR (500 MHz, DMSO-d6): δ 8.88 (s, 1H), 8.03 (s, 
1H), 7.52-7.50 (m, 2H), 7.18 (b, 1H), 6.63 (b, 1H), 6.27 (t, JHH=7.5 Hz, 1H), 3.04 (q, JHH=7.0 
Hz, 2H), 1.98 (t, JHH=6.5 Hz, 2H), 1.45-1.39 (m, 4H), 1.24-1.20 (m, 22H). 
13C NMR (125 
MHz, DMSO-d6): δ 177.39, 157.95, 143.35, 134.91, 129.78 (d, JCF=30.0 Hz), 127.08 (d, 
JCF=271.2 Hz), 125.32, 124.28, 119.11 (d, JCF=5.2 Hz), 38.22, 32.68, 32.16, 32.15, 32.11, 
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32.09, 32.06, 31.92, 31.83, 29.41, 28.21. HRMS (ESI) (m/z): calcd for C24H38ClF3N3O2 
[M+H]+ 492.2599, found 492.2599. 
16-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-N-methyl-hexadecanamide 
(1-MA): White solid, yield 41%. Mp = 133-135C. 1H NMR (500 MHz, DMSO-d6): δ 8.88 (s, 
1H), 8.04 (d, JHH=2.5 Hz, 1H), 7.63 (b, 1H), 7.53-7.49 (m, 2H), 6.29 (t, JHH=5.5 Hz, 1H), 3.06 
(q, JHH=7.0 Hz, 2H), 2.68 (s, 3H), 2.01 (t, JHH=7.5 Hz, 2H), 1.45-1.38 (m, 4H), 1.24-1.20 (m, 
22H). 13C NMR (125 MHz, DMSO-d6): δ 209.60, 175.58, 157.96, 143.35, 134.91, 129.77 (d, 
JCF=30.0 Hz, 1C), 127.06 (d, JCF=271.2 Hz, 1C), 125.32, 124.27, 119.16, 38.44, 33.80, 32.68, 
32.16, 32.14, 32.12, 32.00, 32.03, 31.89, 31.83, 31.81, 29.41, 28.49, 28.37. HRMS (ESI) (m/z): 
calcd for C25H40ClF3N3O2 [M+H]
+ 506.2755, found 506.2756. 
 
Preparation of 16-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-N-
(tetrahydro-2H-pyran-2-yloxy)hexadecanamide (2). To a solution of 1 (0.150 g, 0.304 
mmol) in anhydrous DMF (10 mL) under nitrogen were added 1-hydroxybenzotriazole hydrate 
(0.060 g, 0.365 mmol), and NMM (0.100 mL, 0.912 mmol). The solution was stirred at room 
temperature for 30 minutes, then O-tetrahydro-2-H-pyran-2-yl-hydroxyamine (0.110 g, 0.942 
mmol) was added and stirring was continued for 18 h. The resulting mixture was diluted with 
water (80 mL) and extracted with chloroform (3×30 mL). The combined organic layer was 
washed with water (3×100 mL), saturated aqueous sodium bicarbonate (NaHCO3, 30 mL), and 
brine (30 mL) and then concentrated in vacuo. The crude product was purified on silica gel by 
stepwise gradient elution with dichloromethane/isopropanol (95:5 to 80:20), affording 2 as a 
white solid (0.120 g, 67%). Mp = 116-118C. 1H NMR (500 MHz, DMSO-d6): δ 10.85 (s, 1H), 
8.88 (s, 1H), 8.05 (d, JHH=2.0 Hz, 1H), 7.54-7.50 (m, 2H), 6.29 (t, JHH=5.0 Hz, 1H), 4.77 (s, 
1H), 3.92-3.87 (m, 1H), 3.48-3.46 (m, 1H), 3.08 (q, JHH=6.5 Hz, 2H), 1.96 (t, JHH=7.0 Hz, 2H), 
1.65-1.59 (m, 3H), 1.51-1.39 (m, 7H), 1.25-1.21 (m, 22H). 13C NMR (125 MHz, DMSO-d6): 
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δ 172.16, 157.95, 143.34, 134.93, 129.78 (d, JFC=30.0 Hz), 127.07 (d, JCF=271.2 Hz), 125.32, 
124.27, 119.14 (d, JCF=5.8 Hz), 103.25, 64.38, 35.27, 32.69, 32.16, 32.11, 32.04, 31.85, 31.56, 
30.90, 29.42, 28.06, 27.80, 21.42. HRMS (ESI) (m/z): calcd for C29H46ClF3N3O4 [M+H]
+ 
592.3123, found 592.3123.  
 
Preparation of 16-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-N-
hydroxyhexadecanamide (1-HA). To a solution of 2 (0.090 g, 0.152 mmol) in methanol (10 
mL) was added 1M HCl (1 mL) dropwise. The suspension was stirred for 6 h at room 
temperature, and then concentrated in vacuo. The off-white solid was triturated with 
methanol/water (50:50) followed by acetone and dried under vacuum to yield 1-HA as an off-
white solid (0.062 g, 80%). Mp = 114-117C. 1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H), 
8.90 (s, 1H), 8.64 (d, JHH=1.5 Hz, 1H), 8.05 (d, JHH=2.0 Hz, 1H), 7.53 (m, 2H), 6.31 (t, JHH=6.0 
Hz, 1H), 3.07 (q, JHH=6.5 Hz, 2H), 1.92 (t, JHH=7.0 Hz, 2H), 1.45-1.39 (m, 4H), 1.24-1.21 (m, 
22H). 13C NMR (125 MHz, DMSO-d6): δ 172.21, 157.95, 143.34, 134.93, 130.12 (d, JCF=30.0 
Hz), 127.07 (d, JCF=271.2 Hz), 125.32, 124.27, 119.09 (d, JCF=5.8 Hz), 35.36, 32.69, 32.17, 
31.85, 31.70, 29.42, 28.23. HRMS (ESI) (m/z): calcd for C24H38ClF3N3O3 [M+H]
+ 508.2548, 
found 508.2547.  
 
Preparation of 2-(15-hydroxypentadecyl)-1H-isoindole-1,3(2H)-dione (4). 15-bromo-1-
pentadecanol (3, 3.000 g, 9.77 mmol) and potassium phthalimide (2.352 g, 12.70 mmol) were 
dissolved in anhydrous DMF (50 mL) under a nitrogen atmosphere. The solution was refluxed 
for 18 h and cooled to room temperature. The resulting mixture was filtered and the filter bed 
was washed with diethyl ether (50 mL). The filtrate was washed with distilled water (3×200 
mL) and brine (2×100 mL), and then concentrated under reduced pressure. The crude product 
was purified on silica gel by stepwise gradient elution with dichloromethane/ethyl acetate (95:5 
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to 70:30), yielding 4 as a white solid (2.230 g, 61%). Mp = 105-109C. 1H NMR (500 MHz, 
CDCl3): δ 7.84 (dd, JHH=5.5, 3.5 Hz, 2H), 7.71 (dd, JHH=5.5, 3.5 Hz, 2H), 3.68-3.61 (m, 4H), 
1.67 (p, JHH=7.0 Hz, 2H), 1.58 (p, JHH=8.0 Hz, 2H), 1.32-1.24 (m, 22H). 
13C NMR (125 MHz, 
CDCl3): δ 209.59, 171.14, 136.47, 134.85, 125.79, 65.76, 40.74, 35.47, 33.57, 32.26, 32.25, 
32.23, 32.21, 32.19, 32.11, 32.07, 31.83, 31.25, 29.52, 28.38. HRMS (ESI) (m/z): calcd for 
C23H36NO3 [M+H]
+ 374.2689, found 374.2690. 
 
Preparation of 15-aminopentadecan-1-ol (5). To a solution of 4 (2.230 g, 5.97 mmol) in 
anhydrous tetrahydrofuran (THF, 70 mL) under a nitrogen atmosphere was added hydrazine 
monohydrate (7 mL, 95 mmol). The resulting mixture was refluxed for 18 h and cooled to room 
temperature. The solvent and the excess of hydrazine were removed under reduced pressure. 
The crude product was extracted with dichloromethane (200 mL) and aqueous sodium 
hydroxide (0.5M, 200 mL). The organic layer was separated and washed with aqueous sodium 
hydroxide (1M, 100 mL) and distilled water (2×100 mL), and then concentrated in vacuo, 
yielding 5 as an off-white solid (1.410 g, 96%). Mp = 58-60C. 1H NMR (500 MHz, CDCl3): 
δ 3.59 (t, JHH=6.5 Hz, 2H), 2.62 (t, JHH=7.0 Hz, 2H), 1.51 (p, JHH=7.5 Hz, 2H), 1.38 (p, JHH=7.0 
Hz, 2H), 1.29-1.19 (m, 22H). 13C NMR (125 MHz, CDCl3): δ 65.65, 44.93, 36.52, 35.49, 32.24, 
32.22, 32.19, 32.13, 32.06, 29.53, 28.40. HRMS (ESI) (m/z): calcd for C15H34NO [M+H]
+ 
244.2634, found 244.2634. 
 
Preparation of 15-bromopentadecan-1-aminium bromide (6). A solution of 5 (1.410 g, 5.8 
mmol) and hydrobromic acid 48% (70 mL) was refluxed for 18 h. The mixture was 
concentrated in vacuo and then the residue was recrystallized twice with hot acetone to afford 
6 as an off-white solid (1.611 g, 72%). Mp = 157-159C. 1H NMR (500 MHz, CDCl3): δ 8.00 
(b, 2H), 3.42 (t, JHH=6.5 Hz, 2H), 3.02 (t, JHH=6.5 Hz, 2H), 1.87 (p, JHH=7.5 Hz, 2H), 1.82 (p, 
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JHH=7.5 Hz, 2H), 1.41 (p, JHH=7.5 Hz, 2H), 1.29-1.25 (m, 20H). 
13C NMR (125 MHz, CDCl3): 
δ 62.01, 41.24, 32.83, 31.81, 28.69, 28.56, 28.54, 28.51, 28.45, 28.38, 25.86, 24.71. HRMS 
(ESI) (m/z): calcd for C15H34Br2N [M+H]
+ 306.1791, found 306.1792. 
 
Preparation of 1-(15-bromopentadecyl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea (7). 
To a suspension of 6 (2.000 g, 5.16 mmol) in anhydrous THF (40 mL) under nitrogen at room 
temperature were added 4-chloro-3-(trifluoromethyl)phenyl isocyanate (1.372 g, 6.19 mmol) 
and triethylamine (0.720 mL, 5.16 mmol). The mixture was stirred for 4 h, and then 
concentrated under reduced pressure. The residue was purified on silica gel by stepwise 
gradient elution with petroleum/ethyl acetate (90:10 to 20:80) to afford 7 as a white solid (2.470 
g, 91%). Mp = 88-92C. 1H NMR (500 MHz, CDCl3): δ 7.63 (d, JHH=1.5 Hz, 1H), 7.54 (dd, 
JHH=8.5, 2.0 Hz, 1H), 7.38 (d, JHH=9.0 Hz, 1H), 6.70 (b, 1H), 4.84 (t, JHH=5.5 Hz, 1H), 3.43 
(t, JHH=6.5 Hz, 2H), 3.26 (q, JHH=7.0 Hz, 2H), 1.87 (p, JHH=7.5 Hz, 2H), 1.53 (p, JHH=7.0 Hz, 
2H), 1.42 (p, JHH=7.0 Hz, 2H), 1.28-1.24 (m, 20H). 
13C NMR (125 MHz, CDCl3): δ 157.48, 
134.69, 133.64, 131.59 (d, JCF=31.0 Hz), 128.44 (d, JCF=248.0 Hz), 126.31, 124.13, 121.23, 
43.33, 36.75, 35.49, 32.62, 32.56, 32.26, 32.25, 32.21, 32.19, 32.17, 32.08, 31.93, 31.41, 30.82, 
29.51. HRMS (ESI) (m/z): calcd for C23H36BrClF3N2O [M+H]
+ 527.1646, found 527.1647. 
 
Preparation of sodium 15-({[4-chloro-3-
(trifluoromethyl)phenyl]carbamoyl}amino)pentadecane-1-sulfonate (1-SA). A solution of 
7 (0.150 g, 0.284 mmol) and sodium sulfite (0.072 g, 0.568 mmol) in 3:2 ethanol/water (10 
mL) was refluxed for three days and cooled to room temperature. The volume of the reaction 
mixture was reduced to half under pressure. The solution was adjusted to pH = 8 with aqueous 
sodium hydroxide (1.5M, 2 mL), and distilled water (10 mL) was added. The water was then 
removed by freeze-drying. The resulting solid was triturated twice with 1:1 ethanol/water, and 
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then diethyl ether to yield 1-SA as a white solid (0.070 g, 45%). Mp = 185C (decomp.). 1H 
NMR (500 MHz, DMSO-d6): δ 9.21 (s, 1H), 8.08 (d, JHH=2.0 Hz, 1H), 7.59 (dd, JHH=9.0, 2.5 
Hz, 1H), 7.51 (d, JHH=8.5 Hz, 1H), 6.68 (t, JHH=5.5 Hz, 1H), 3.06 (q, JHH=12.5 Hz, 2H), 2.41 
(t, JHH=8.0 Hz, 2H), 1.56 (p, JHH=8.0 Hz, 2H), 1.40 (p, JHH=6.0 Hz, 2H), 1.24-1.22 (m, 22H). 
13C NMR (125 MHz, DMSO-d6): δ 158.08, 143.62, 134.85, 129.20 (d, JCF=31.0 Hz), 126.03 
(d, JCF=271.0 Hz), 125.24, 124.07, 119.05 (d, JCF=5.2 Hz), 54.68, 32.58, 32.15, 31.78, 31.71, 
31.70, 31.68, 31.67, 31.57, 31.51, 31.37, 29.36, 28.11. HRMS (ESI) (m/z): calcd for 
C23H36ClF3N2O4S [M+H]
+ 529.2109, found 529.2108. 
 
Preparation of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(15-cyanopentadecyl)urea (8). 
To a solution of 7 (0.300 g, 0.569 mmol) in DMSO (20 mL) was added sodium cyanide (0.084 
g, 1.71 mmol) at 40C. The resulting mixture was stirred for 18 h, and then cooled to room 
temperature. The resulting mixture was diluted with water (50 mL) and extracted with 
chloroform (3×100 mL). The organic layer was separated, washed with distilled water (2×100 
mL) and brine (100 mL), and then concentrated in vacuo. The off-white solid was triturated 
twice with water, followed by diethyl ether and dried under vacuum to yield 8 as a white solid 
(0.218 g, 81%). Mp = 89-93C. 1H NMR (500 MHz, CDCl3): δ 7.66 (d, JHH=2.5 Hz, 1H), 7.57 
(dd, JHH=8.5, 2.5 Hz, 1H), 7.39 (d, JHH=8.5 Hz, 1H), 3.26 (t, JHH=7.0 Hz, 1H), 2.37 (t, JHH=7.0 
Hz, 2H), 1.68 (p, JHH=7.0 Hz, 2H), 1.53 (p, JHH=7.5 Hz, 2H), 1.45 (p, JHH=8.0 Hz, 2H), 1.30-
1.26 (m, 20H). 13C NMR (125 MHz, CDCl3): δ 157.64, 140.63, 134.57, 131.31 (d, JCF=31.3 
Hz), 127.91, 125.24 (d, JCF=272.2 Hz), 125.87, 122.71, 120.82 (d, JCF=5.7 Hz), 43.14, 32.61, 
32.06, 32.01, 31.99, 31.90, 31.88, 31.76, 31.28, 31.24, 29.49, 27.93, 19.80. HRMS (ESI) (m/z): 
calcd for C24H36ClF3N3O [M+H]
+ 474.2493, found 474.2495.  
Preparation of (1E/Z)-16-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-N'-
hydroxy-hexadecanimidamide (9). To a solution of 8 (0.130 g, 0.274 mmol) in methanol (20 
23 
mL) was added aqueous hydroxylamine solution (50 wt %, 1.2 mL). The mixture was refluxed 
for 18 h, and then cooled to room temperature. The solvent was removed under reduced 
pressure. The off-white solid was triturated twice with water, followed by diethyl ether and 
dried under vacuum to yield 9 as an off-white solid (0.140 g, 97%). Mp = 98-103C. 1H NMR 
(500 MHz, DMSO-d6): δ 8.88 (b, 1H), 8.63 (s, 1H), 8.04 (d, JHH=2.0 Hz, 1H), 7.53-7.52 (m, 
2H), 6.28 (t, JHH=5.5 Hz, 1H), 5.25 (b, 2H), 3.06 (q, JHH=6.0 Hz, 2H), 1.92 (t, JHH=6.5 Hz, 
2H), 1.44-1.40 (m, 4H), 1.25-1.20 (m, 22H). 13C NMR (125 MHz, DMSO-d6): δ 157.96, 
155.94, 143.34, 134.92, 129.67 (d, JCF=30.1 Hz), 125.99 (d, JCF=271.2 Hz), 125.33, 124.31, 
119.15 (d, JCF=5.8 Hz), 82.28, 33.89, 33.81, 32.69, 32.17, 32.16, 32.12, 32.09, 31.93, 31.84, 
31.76, 29.47, 29.41. HRMS (ESI) (m/z): calcd for C24H39ClF3N4O2 [M+H]




thiadiazol-3-yl)pentadecyl]urea (1-OT). To a solution of 9 (0.200 g, 0.395 mmol) in 
anhydrous THF (15 mL) under nitrogen was added 1,1′-thiocarbonyldiimidazole (0.141 g, 
0.789 mmol). The resulting mixture was stirred for 2 h, and then concentrated under reduced 
pressure. The crude product was dissolved in acetonitrile (20 mL) and heated to 90C. 1,8-
Diazabicycloundec-7-ene (0.25 mL, 1.580 mmol) was added to the mixture at room 
temperature and stirred for 18 h. The resulting mixture was diluted with water (20 mL). The 
solution was adjusted to pH 1 with HCl 1M, and then extracted with chloroform (3×20 mL). 
The organic layer was washed with water (3×100 mL) and brine (30 mL), and then 
concentrated in vacuo. The crude product was purified on silica gel by stepwise gradient elution 
with dichloromethane/isopropyl alcohol (98:2 to 80:20) yielding 1-OT as an off-white solid 
(0.030 g, 14%). Mp = 80-84C. 1H NMR (500 MHz, DMSO-d6): δ 8.87 (s, 1H), 8.03 (d, 
JHH=2.0 Hz, 1H), 7.52-7.49 (m, 2H), 6.28 (t, JHH=6.0 Hz, 1H), 3.06 (q, JHH=13.0 Hz, 2H), 2.56 
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(t, JHH=7.5 Hz, 2H), 1.59 (t, JHH=6.5 Hz, 2H), 1.38 (t, JHH=6.5 Hz, 2H), 1.23-1.20 (m, 22H). 
13C NMR (125 MHz, DMSO-d6): δ 187.70, 162.22, 155.29, 140.67, 132.25, 127.11 (d, 
JCF=30.3 Hz), 124.41 (d, JCF=271.7 Hz), 122.66, 121.62, 116.49 (d, JCF=5.3 Hz), 30.02, 29.48, 
29.46, 29.45, 29.42, 29.39, 29.20, 29.16, 28.86, 28.58, 26.74, 25.58, 23.71. HRMS (ESI) (m/z): 
calcd for C25H37ClF3N4O2S [M+H]
+ 549.2272, found 549.2270. 
 
Cell-based assays 
General: Human MDA-MB-231 breast cancer cells were obtained from ATCC (Manassas, 
VA). Cells were cultured in Dulbecco’s Modified Eagle Medium containing 10% fetal bovine 
serum (Thermo Fischer Scientific, Waltham, MA) and 1% penicillin/streptomycin 
(Invitrogen), at 37 °C in humidified 5% CO2 in air. Confluent cells (80−90%) were harvested 
with trypsin/EDTA after washing in phosphate-buffered saline (PBS; Amresco, Solon, OH). 
Compounds were added to cells in DMSO (Sigma-Aldrich). 
ATP and caspase 3/7 assays: MDA-MB-231 cells were seeded in triplicate into black-walled 
96-well plates at a cell density of 1x104 cells/well and 24 h later serum was removed. Cells 
were treated with various concentrations of the test compounds for 24 or 48 h; control cells 
received serum-free DMEM alone. Following treatments, ATP formation and caspase 3/7 
activity was determined using commercial kits (CellTiter-Glo® luminescent cell viability assay 
and Caspase-Glo, respectively; Promega; Annandale, NSW, Australia). 
Cell cycle kinetics: MDA-MB-231 cells were seeded at a density of 7.5x104 cells/well in 12-
well plates and allowed to adhere overnight. After serum starvation for 24 h, the cells were 
treated with test compounds (10 µM) in DMSO for 24 or 48 h; control cells received serum-
free DMEM alone. Cells were trypsinized, washed with PBS and fixed overnight with cold 
ethanol (80%, -20°C). The cells were washed twice with PBS and resuspended in 0.1M PBS 
containing 0.1 mg/mL DNase-free RNase A and 0.1% NP40. The cells were incubated on ice 
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for 1 h with propidium iodide and analysed as described previously in a Gallios flow cytometer 
(Beckman Coulter Australia, Lane Cove, NSW).[10] 
Annexin V/7AAD: Annexin V/7AAD staining in treated MDA-MB 231 cells (7.5 x 104 
cells/well) was assessed in 12-well plates. Twenty four h after serum removal the cells were 
treated with compounds (10 µM) for 24 or 48 h. Treated cells were trypsinized and washed 
twice with cold PBS, stained with annexin V and 7AAD for analysis in a GalliosTM flow 
cytometer (Beckman Coulter Australia).[15] 
JC-1 assay: MDA-MB-231 cells were seeded in triplicate in 96-well plates (1x104 cells/well) 
and 24 h later serum was removed. Cells were treated with various concentrations of the test 
compounds for 24 or 48 h; control cells received serum-free DMEM alone. Cells were 
incubated with JC-1 in serum-free medium (37°C, 20 min) and the JC-1 red:green ratio was 
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ABBREVIATIONS USED 
7AAD, 7-aminoactinomycin; CYP, cytochrome P450; EDCI, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; EET, epoxyeicosatrienoic acid; 
HRMS, High resolution mass spectrometry; JC-1, 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide; NMM, N-methylmorpholine; PUFA, 
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Scheme 1. Synthesis of the amide analogues 1-A and 1-MA, and the hydroxamic acid 
analogue 1-HA. Reagents and conditions: (i) EDCI, HOBT and NMM, and then 
either ammonium chloride or methylammonium chloride (anhydrous DMF, rt, 18 
h), (ii) 1M HCl, methanol, rt, 6 h.  
Scheme 2. Synthesis of oxo-thiadiazole (1-OT) and sulfonic acid (1-SA) isosteres. Reagents 
and conditions: (i) potassium phthalimide, anhydrous DMF, N2, reflux, 18 h; (ii) 
hydrazine, THF, reflux, 18 h; (iii) HBr, reflux, 18 h; (iv) 4-chloro-3-
(trifluoromethyl)phenyl isocyanate, triethylamine, anhydrous THF, N2, rt, 4 h; (v) 
sodium sulfite, ethanol/water (3:2), reflux, 3 d; (vi) NaCN, 40°C, DMSO, 24 h; 
(vii) HONH2, methanol, reflux, 18 h; (viii) a. 1,1′-thiocarbonyldiimidazole, 
anhydrous THF, rt, 2 h; b. diazabicycloundec-7-ene, ACN, 90°C to rt, 18 h.  
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Figure 1.  (A) Effect of 1 analogues (10 µM) on ATP formation by MDA-MB-231 cells after 
24 and 48 h of treatment; (B) Flow cytometric analysis of MDA-MB-231 cells after 
treatment with 1 analogues (10 µM) for 24 and 48 h. Areas in histograms 
corresponding to sub-G1, G0/G1, S and G2/M phases are shown in control (CTL) 
cells. Histograms were obtained after 24 h unless indicated otherwise. All data are 
mean±SEM from three separate experiments. Different from DMSO-treated 
control: ***P<0.001, **P<0.01, *P<0.05.  
Figure 2. (A) Effect of 1 analogues (10 µM) on caspase-3/7 activity in MDA-MB-231 cells 
after 24 and 48 h of treatment; (B) annexin V-FITC/7AAD staining in MDA-MB-
231 cells after treatment with 1 analogues (10 µM) for 24 or 48 h. Areas 
corresponding to 7AAD-stained cells (upper left quadrant), annexin V-stained cells 
(lower right quadrant), dual 7AAD and annexin V-stained cells (upper right 
quadrant) and unstained live cells (lower left quadrant) are shown in control (CTL) 
cells. Images showing cell distributions were obtained after 24 h of treatment; (C) 
JC-1 ratios in MDA-MB-231 cells treated with various concentrations of 1 
analogues. All data are mean±SEM from three separate experiments. Different 
from DMSO-treated control: *P<0.001, **P<0.01, *P<0.05. 
